Questions Swirl Around Trump’s Potential Impact on Specialty Drugs

Jan 09
Jan 09, 2025

During the prior administration of Donald Trump, the then-president talked often about taking on pharmaceutical companies and PBMs over high spending on prescription drugs but did not accomplish all he set out to do. Since his reelection, PBMs in particular have been in his crosshairs, as he criticized the “rich as hell” and “horrible” middlemen, which he vowed to “knock out.” And with a potential cabinet of many newcomers to Capitol Hill — some of whom have openly criticized how HHS, including the FDA, is run — questions remain about the upcoming administration’s impact on health care, including how it could impact the specialty drug space. For our annual series of outlook stories on the year ahead, industry experts weigh in on the Trump effect. (Editor’s note: These comments have been edited for length and clarity.)
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.